Evidence map›Paper›PMID 38383057›Full record

ArticleHIV medicine2024

Framingham risk score based vascular outcomes in acute versus chronic HIV cohorts after 6 years of ART.

Kathryn Brown Holroyd, Win Min Han, Tanakorn Apornpong, Lydie Trautmann, Sivaporn Gatechompol, Akarin Hiransuthikul, Sasiwimol Ubolyam, Carlo Sacdalan, Somchai Sriplienchan, Ratchapong Kanaprach and 4 more

Open access · hybridAbstract read
In one paragraph

Article in HIV medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Kathryn Brown HolroydDepartment of Neurology, Yale University, New Haven, Connecticut, USA.ORCID 0000-0001-5884-9734
Win Min HanHIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.ORCID 0000-0003-3731-7960
Tanakorn ApornpongHIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Lydie TrautmannU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Sivaporn GatechompolHIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Akarin HiransuthikulHIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.ORCID 0000-0003-1906-8171
Sasiwimol UbolyamHIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Carlo SacdalanSEARCH Research Foundation, Bangkok, Thailand.
Somchai SriplienchanSEARCH Research Foundation, Bangkok, Thailand.
Ratchapong KanaprachSEARCH Research Foundation, Bangkok, Thailand.
Stephen KerrHIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Anchalee AvihingsanonHIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Serena SpudichDepartment of Neurology, Yale University, New Haven, Connecticut, USA.
Phillip ChanDepartment of Neurology, Yale University, New Haven, Connecticut, USA.
Chulalongkorn University · THYale University · USHIV Netherlands Australia Thailand Research Collaboration · THHenry M. Jackson Foundation · USUNSW Sydney · AU

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Impact of IL-15 immunotherapy on tissue-specific CD8 T cells to reduce the CNS HIV reservoir seeding and persistenceR01MH130197 · NIMH · OREGON HEALTH & SCIENCE UNIVERSITY · PI Lishomwa C Ndhlovu, Afamefuna Okoye · 2022 to 2026
$5.1M
Longitudinal determination of nervous system consequences of SARS-CoV-2 in virologically suppressed people with HIV-1 treated in early infectionRF1MH132356 · NIMH · YALE UNIVERSITY · PI PAUL, ROBERT HARRIS, SPUDICH, SERENA S · 2022 to 2022
$3.2M
Advancement of Military Medicine, IncDivision of AIDSGilead SciencesHIV-NATMerck and ViiV HealthcareNational Institute of Allergy and Infectious DiseasesNational Institutes of Health (DAIDS, NIAID, NIH) AAI21058-001-01000National Institutes of Mental Health (NIMH) R01MH130197National Institutes of Mental Health (NIMH) R01MH132356NCATS NIH HHS UL1 TR001863NIMH NIH HHS R01 MH130197NIMH NIH HHS RF1 MH132356RV254/SEARCH 010 W81XWH-18-2-0040Thai Government Pharmaceutical OrganizationThai Red Cross AIDS Research CentreU.S. Department of Defence
6 · The paper itself

Abstract

introductionImmune dysregulation persists in people with HIV (PWH) on antiretroviral therapy (ART) and may lead to accelerated vascular ageing and cardiovascular disease (CVD). While delayed time to initiation of ART has been linked to worse cardiovascular outcomes, the effect of ART initiation during acute infection on these outcomes is not well understood.

methodsParticipants were enrolled from the SEARCH010/RV254 acute HIV (AHI) and HIV-NAT chronic HIV (CHI) cohorts in Thailand. Participants with 6-year follow-up and viral suppression (viral load < 50 copies/μL) at follow-up were included. Both unmatched cohorts and age and gender-matched cohorts were analysed. Demographics, HIV laboratories, and cardiovascular risk factors from enrolment and 6-year follow-up were obtained from electronic records. Framingham Risk Score (FRS), vascular age (VA), vascular age deviation (VAD), and 10-year atherosclerotic cardiovascular disease (ASCVD) risk were calculated from previously published equations. Vascular outcomes in AHI and CHI cohorts were compared, and univariable and multivariable linear regression analyses were used to investigate risk factors associated with worse vascular scores.

resultsIn all, 373 AHI participants and 608 CHI participants were identified. AHI participants were of younger age, had a higher prevalence of syphilis and a lower prevalence of prior hepatitis B, tuberculosis, diabetes, and hypertension. Higher CD4 T-cell and lower CD8 T-cell counts were seen in the AHI cohort at enrolment and 6-year follow-up. In all participants, the AHI cohort had a lower median FRS (p < 0.001) and VA (p < 0.001), but higher VAD (p < 0.001). However, in matched cohorts, no differences were found in FRS-based outcomes. In all participants, higher VAD after 6 years of ART was associated with higher body mass index (p < 0.001) and higher CD4 count (p < 0.001), which persisted in multivariable analysis. When FRS components were analysed individually, CD4 count was associated only with male sex and cholesterol.

conclusionsWe did not identify differences in FRS-based vascular outcomes at 6 years in matched cohorts of participants who started ART during AHI versus CHI. We identified a correlation between higher CD4 count and worse FRS-based vascular outcomes, which may be driven by underlying metabolic risk factors. Further study is needed to confirm these findings and evaluate underlying mechanisms.

Indexed as

HIV InfectionsAdultAnti-HIV AgentsAnti-Retroviral AgentsCardiovascular DiseasesCD4 Lymphocyte CountCohort StudiesFemaleHumansMaleMiddle AgedRisk AssessmentRisk FactorsThailandViral LoadAnti-HIV AgentsAnti-Retroviral Agentsacute HIVcardiovascular riskCD4 T‐cell countFramingham risk scoreHIVvascular age

Identifiers

PMID38383057
PMCPMC11153003
OpenAlexW4392775049

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.